Robert F. Kennedy Jr., who endorsed President-elect Donald Trump after suspending his own 2024 campaign, is making headlines with his calls to eliminate underperforming divisions at the Food and Drug Administration (FDA). In a recent interview, Kennedy specifically targeted the FDA’s nutrition department, arguing that it “has to go” due to its failure to serve public health.
Kennedy has clarified that he isn’t pushing for the agency’s total shutdown but rather aims to reform it by removing “corruption.” His remarks suggest a selective approach to restructuring. “There are entire departments … that have to go,” he said, pointing to inefficiencies within the FDA that he believes compromise its mission.
BREAKING: Robert F. Kennedy Jr. says he intends to clear out entire departments of the FDA. pic.twitter.com/Ho10s5T6gU
— Leading Report (@LeadingReport) November 6, 2024
Kennedy’s possible role in Trump’s administration has become a topic of speculation, particularly after he confirmed discussions with Trump. According to Kennedy, he is “developing a proposal” for his role, and some believe he could be considered for secretary of Health and Human Services (HHS) or another health-focused position not requiring Senate confirmation.
Kennedy’s endorsement of Trump brought him considerable support among moderates and independents, a shift from his earlier role as a Democratic primary challenger. Many credit Kennedy’s backing as a critical factor that broadened Trump’s appeal, helping him to secure a significant victory.
FDA’s war on public health is about to end. This includes its aggressive suppression of psychedelics, peptides, stem cells, raw milk, hyperbaric therapies, chelating compounds, ivermectin, hydroxychloroquine, vitamins, clean foods, sunshine, exercise, nutraceuticals and anything…
— Robert F. Kennedy Jr (@RobertKennedyJr) October 25, 2024
Should Donald Trump and Robert Kennedy Jr. completely dismantle the FDA? 🤔 pic.twitter.com/OMMrS0eEta
— Gain of Fauci (@DschlopesIsBack) November 7, 2024
Should Kennedy join the administration, his reform-driven approach may prompt considerable changes within health agencies, with a focus on streamlining structures and improving accountability. His stance on the FDA aligns with Trump’s agenda of reducing bureaucracy to increase government efficiency.
Kennedy’s calls for FDA reform and his potential place in Trump’s administration could lead to notable changes in health policy. His approach reflects a larger desire within Trump’s team to improve agency effectiveness, potentially reshaping the role of federal health agencies in addressing public needs.
